New carriers and adjuvants in the development of vaccines.
Different approaches are being followed to enhance the immunogenicity of established and newly developed vaccines. Some of them foresee the utilization of carrier molecules recognized by the immune systems of a large proportion of the human population. Others are directed mainly towards the development of improved adjuvants and delivery systems.
Del Giudice
G
G
World Health Organization, University of Geneva, Switzerland.
D000276:Adjuvants, Immunologic; D000818:Animals; D000917:Antibody Formation; D000938:Antigen-Presenting Cells / Q000276:immunology; D002352:Carrier Proteins / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014612:Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D002352:Carrier Proteins; D014612:Vaccines